{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:11:28Z","timestamp":1770761488778,"version":"3.50.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01003-z","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T15:59:09Z","timestamp":1619625549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-8883","authenticated-orcid":false,"given":"David F. L.","family":"Liew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Dau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmj.333.7558.60-a","volume":"333","author":"R Watson","year":"2006","unstructured":"Watson R. Health spending rising faster than GDP in most rich countries. BMJ. 2006;333:60.","journal-title":"BMJ."},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"j437","DOI":"10.1136\/bmj.j437","volume":"356","author":"M Gray","year":"2017","unstructured":"Gray M. Value based healthcare. BMJ. 2017;356:j437.","journal-title":"BMJ."},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.5694\/mja12.11083","volume":"197","author":"AG Elshaug","year":"2012","unstructured":"Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low-value health care practices: an Australian study. Med J Aust. AMPCo. 2012;197:556\u201360.","journal-title":"Med J Aust. AMPCo"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/bmj.325.7370.961","volume":"325","author":"JE Wennberg","year":"2002","unstructured":"Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325:961\u20134.","journal-title":"BMJ."},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2522\/ptj.20090173","volume":"90","author":"GM Rutten","year":"2010","unstructured":"Rutten GM, Degen S, Hendriks EJ, Braspenning JC, Harting J, Oostendorp RA. Adherence to clinical practice guidelines for low back pain in physical therapy: do patients benefit? Phys Ther. 2010;90:1111\u201322.","journal-title":"Phys Ther."},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41584-020-00552-4","volume":"17","author":"PC Robinson","year":"2021","unstructured":"Robinson PC, van der Linden S, Khan MA, Taylor WJ. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol. 2021;17:109\u201318 This paper discusses the issues with diagnosis and the challenges of using imaging for diagnosis.","journal-title":"Nat Rev Rheumatol"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","volume":"6","author":"PC Robinson","year":"2019","unstructured":"Robinson PC, Sengupta R, Siebert S. Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy. Rheumatol Ther. 2019;6:165\u201377.","journal-title":"Rheumatol Ther."},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11926-013-0317-3","volume":"15","author":"WJ Taylor","year":"2013","unstructured":"Taylor WJ, Robinson PC. Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. Curr Rheumatol Rep. 2013;15:317.","journal-title":"Curr Rheumatol Rep."},{"key":"1003_CR9","first-page":"229","volume":"35","author":"GP Thomas","year":"2017","unstructured":"Thomas GP, Willner D, Robinson PC, Cortes A, Duan R, Rudwaleit M, et al. Genetic diagnostic profiling in axial spondyloarthritis: a real world study. Clin Exp Rheumatol. 2017;35:229\u201333.","journal-title":"Clin Exp Rheumatol."},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.berh.2015.08.001","volume":"29","author":"M-E Costello","year":"2015","unstructured":"Costello M-E, Robinson PC, Benham H, Brown MA. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;29:202\u201312.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.38967","volume":"67","author":"M-E Costello","year":"2015","unstructured":"Costello M-E, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2015;67:686\u201391.","journal-title":"Arthritis Rheumatol."},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/annrheumdis-2014-207151","volume":"74","author":"D Poddubnyy","year":"2015","unstructured":"Poddubnyy D, van Tubergen A, Landew\u00e9 R, Sieper J, van der Heijde D. Assessment of SpondyloArthritis international Society (ASAS). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis. 2015;74:1483\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1136\/annrheumdis-2014-205358","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, O\u2019Rourke M, Ramasamy P, Murphy CC, FitzGerald O. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis. 2015;74:1990\u20135.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR14","doi-asserted-by":"crossref","unstructured":"Habibi S, Doshi S, Sengupta R. THU0413 utility of the spade tool to identify axial spondyloarthritis in patients with chronic backpain. 2016. ard.bmj.com. Available from: https:\/\/ard.bmj.com\/content\/75\/Suppl_2\/338.2.abstract.","DOI":"10.1136\/annrheumdis-2016-eular.1687"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-020-00924-5","volume":"22","author":"D Poddubnyy","year":"2020","unstructured":"Poddubnyy D, Sieper J. Treatment of axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep. 2020;22:47.","journal-title":"Curr Rheumatol Rep."},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2012-201777","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, Srinivasan S, Zamani O, Mielants H, Choquette D, Pavelka K, et al. Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis. 2013;72:1621\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3899\/jrheum.110070","volume":"38","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Vahldiek J, Spiller I, Buss B, Listing J, Rudwaleit M, et al. Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol. 2011;38:2452\u201360.","journal-title":"J Rheumatol."},{"key":"1003_CR18","unstructured":"Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, et al. Recognition of inflammatory back pain by US healthcare providers and barriers to specialist referral. Arthritis Rheumatol. Wiley 111 River St, Hoboken 07030-5774, NJ USA; 2019."},{"key":"1003_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/rheumatology\/kex518","volume":"57","author":"MH Derakhshan","year":"2018","unstructured":"Derakhshan MH, Pathak H, Cook D, Dickinson S, Siebert S, Gaffney K, et al. Services for spondyloarthritis: a survey of patients and rheumatologists. Rheumatology. 2018;57:987\u201396.","journal-title":"Rheumatology"},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.ophtha.2016.03.010","volume":"123","author":"X Juanola","year":"2016","unstructured":"Juanola X, Loza Santamar\u00eda E, Cordero-Coma M, SENTINEL Working Group. Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL interdisciplinary collaborative project. Ophthalmology. 2016;123:1632\u20136.","journal-title":"Ophthalmology."},{"key":"1003_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/acr.22528","volume":"67","author":"N Thom","year":"2015","unstructured":"Thom N, Ritchlin CT, Zhang X, Reveille J, Weisman MH. Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis. Arthritis Care Res. 2015;67:829\u201335.","journal-title":"Arthritis Care Res"},{"key":"1003_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.rdc.2012.08.018","volume":"38","author":"PC Robinson","year":"2012","unstructured":"Robinson PC, Brown MA. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum Dis Clin North Am. 2012;38:539\u201353.","journal-title":"Rheum Dis Clin North Am."},{"key":"1003_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.molimm.2013.06.013","volume":"57","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol. 2014;57:2\u201311.","journal-title":"Mol Immunol."},{"key":"1003_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730\u20138.","journal-title":"Nat Genet"},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.61.6.3","volume":"61","author":"X-F Huang","year":"2020","unstructured":"Huang X-F, Li Z, De Guzman E, Robinson P, Gensler L, Ward MM, et al. Genomewide association study of acute anterior uveitis identifies new susceptibility loci. Invest Ophthalmol Vis Sci. 2020;61:3.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"1003_CR26","unstructured":"Nolan MW, Brown MM, Gertner E. Choosing unwisely: HLA-B27 testing and adherence to choosing wisely practices in a large integrated academic healthcare system. Arthritis Rheumatol. Wiley 111 River St, Hoboken 07030-5774, NJ USA; 2017."},{"key":"1003_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3899\/jrheum.141140","volume":"42","author":"SL Chow","year":"2015","unstructured":"Chow SL, Carter Thorne J, Bell MJ, Ferrari R, Bagheri Z, Boyd T, et al. Choosing wisely: the Canadian Rheumatology Association\u2019s list of 5 items physicians and patients should question. J Rheumatol. 2015;42:682\u20139.","journal-title":"J Rheumatol."},{"key":"1003_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/ar4561","volume":"16","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther. 2014;16:109.","journal-title":"Arthritis Res Ther."},{"key":"1003_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/annrheumdis-2017-211313","volume":"77","author":"MA Brown","year":"2018","unstructured":"Brown MA, Bird PA, Robinson PC, Mease PJ, van den Bosch F, Surian C, et al. Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Ann Rheum Dis. 2018;77:1091\u20133.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11926-015-0535-y","volume":"17","author":"S van der Linden","year":"2015","unstructured":"van der Linden S, Akkoc N, Brown MA, Robinson PC, Khan MA. The ASAS criteria for axial spondyloarthritis: strengths, weaknesses, and proposals for a way forward. Curr Rheumatol Rep. 2015;17:62.","journal-title":"Curr Rheumatol Rep."},{"key":"1003_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/annrheumdis-2012-202073","volume":"72","author":"PC Robinson","year":"2013","unstructured":"Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis. 2013;72:162\u20134.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR33","doi-asserted-by":"publisher","unstructured":"Rusman T, van der Weijden MAC, Nurmohamed MT, Landew\u00e9 RBM, de Winter JJH, Boden BJH, et al. Is treatment in patients suspected of non-radiographic axial spondyloarthritis effective? Six months results of a placebo-controlled trial. Arthritis Rheumatol. 2020; Available from: https:\/\/doi.org\/10.1002\/art.41607.","DOI":"10.1002\/art.41607"},{"key":"1003_CR34","doi-asserted-by":"crossref","unstructured":"Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landew\u00e9 R, et al. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;e000397.","DOI":"10.1136\/rmdopen-2016-000397"},{"key":"1003_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.semarthrit.2015.08.003","volume":"45","author":"JR Millner","year":"2016","unstructured":"Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum. 2016;45:411\u201327.","journal-title":"Semin Arthritis Rheum."},{"key":"1003_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/bjsports-2018-099943","volume":"54","author":"SH Sveaas","year":"2020","unstructured":"Sveaas SH, Bilberg A, Berg IJ, Provan SA, Rollefstad S, Semb AG, et al. High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. Br J Sports Med. 2020;54:292\u20137 This paper demonstrates the value of non-pharmacological therapy in axSpA.","journal-title":"Br J Sports Med"},{"key":"1003_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5694\/mja15.00716","volume":"204","author":"AM Hopkins","year":"2016","unstructured":"Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Med J Aust. 2016;204:64\u20138.","journal-title":"Med J Aust."},{"key":"1003_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1136\/annrheumdis-2011-200333","volume":"70","author":"A Tran-Duy","year":"2011","unstructured":"Tran-Duy A, Boonen A, van de Laar MAFJ, Franke AC, Severens JL. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011;70:2111\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR39","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3899\/jrheum.141277","volume":"42","author":"N Tsifetaki","year":"2015","unstructured":"Tsifetaki N, Migkos MP, Papagoras C, Voulgari PV, Athanasakis K, Drosos AA. Counting costs under severe financial constraints: a cost-of-illness analysis of spondyloarthropathies in a Tertiary Hospital in Greece. J Rheumatol. 2015;42:963\u20137.","journal-title":"J Rheumatol."},{"key":"1003_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q, Zhang X, Yan T, Curtis JR. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther. 2017;19:92.","journal-title":"Arthritis Res Ther."},{"key":"1003_CR41","doi-asserted-by":"publisher","unstructured":"Scott DL. Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. F1000Res. 2016;5. Available from: https:\/\/doi.org\/10.12688\/f1000research.8812.1","DOI":"10.12688\/f1000research.8812.1"},{"key":"1003_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3899\/jrheum.150540","volume":"43","author":"JD Greenberg","year":"2016","unstructured":"Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43:88\u201396.","journal-title":"J Rheumatol."},{"key":"1003_CR43","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","volume":"38","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, von Hin\u00fcber U, Meier F, Tian H, B\u00f6hm K, Jugl SM, et al. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int. 2018;38:2121\u201331.","journal-title":"Rheumatol Int."},{"key":"1003_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40744-018-0124-4","volume":"5","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Song X, Kim G, Park Y. Healthcare utilization and direct costs in patients with ankylosing spondylitis using a large US administrative claims database. Rheumatol Ther. 2018;5:463\u201374.","journal-title":"Rheumatol Ther."},{"key":"1003_CR45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198\u2013206.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR46","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/art.39079","volume":"67","author":"J Yazdany","year":"2015","unstructured":"Yazdany J, Dudley RA, Chen R, Lin GA, Tseng C-W. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis Rheumatol. 2015;67:1474\u201380.","journal-title":"Arthritis Rheumatol."},{"key":"1003_CR47","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71:1599\u2013613.","journal-title":"Arthritis Rheumatol."},{"key":"1003_CR48","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR49","doi-asserted-by":"crossref","unstructured":"Kroon FPB, van der Burg LRA, Ramiro S, Landew\u00e9 RBM, Buchbinder R, Falzon L, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;CD010952.","DOI":"10.1002\/14651858.CD010952.pub2"},{"key":"1003_CR50","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","volume":"59","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology. 2020;59:iv79\u201389.","journal-title":"Rheumatology"},{"key":"1003_CR51","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","volume":"77","author":"RBM Landew\u00e9","year":"2018","unstructured":"Landew\u00e9 RBM. Overdiagnosis and overtreatment in rheumatology: a little caution is in order. Ann Rheum Dis. 2018;77:1394\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/BOR.0000000000000625","volume":"31","author":"PM Machado","year":"2019","unstructured":"Machado PM, Deodhar A. Treat-to-target in axial spondyloarthritis: gold standard or fools\u2019 gold? Curr Opin Rheumatol. 2019;31:344\u20138.","journal-title":"Curr Opin Rheumatol."},{"key":"1003_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/13696998.2018.1539400","volume":"22","author":"R Goeree","year":"2019","unstructured":"Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. J Med Econ. 2019;22:45\u201352.","journal-title":"J Med Econ."},{"key":"1003_CR54","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40273-018-0675-9","volume":"36","author":"P Emery","year":"2018","unstructured":"Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, et al. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018;36:1015\u201327.","journal-title":"Pharmacoeconomics."},{"key":"1003_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3899\/jrheum.17666","volume":"45","author":"E Lubrano","year":"2018","unstructured":"Lubrano E, Perrotta FM, Manara M, D\u2019Angelo S, Addimanda O, Ramonda R, et al. The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis. J Rheumatol. 2018;45:195\u2013201.","journal-title":"J Rheumatol."},{"key":"1003_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","volume":"19","author":"R Micheroli","year":"2017","unstructured":"Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017;19:164.","journal-title":"Arthritis Res Ther."},{"key":"1003_CR57","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276\u201381.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2016.00193","volume":"7","author":"E Moorkens","year":"2016","unstructured":"Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7:193.","journal-title":"Front Pharmacol."},{"key":"1003_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12962-017-0081-8","volume":"15","author":"S Harvard","year":"2017","unstructured":"Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, et al. Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. Cost Eff Resour Alloc. 2017;15:20.","journal-title":"Cost Eff Resour Alloc."},{"key":"1003_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20:1\u2013334 v \u2013 vi.","journal-title":"Health Technol Assess"},{"key":"1003_CR61","doi-asserted-by":"crossref","unstructured":"Inman R, Sieper J. Oxford textbook of axial spondyloarthritis: Oxford University Press; 2016.","DOI":"10.1093\/med\/9780198734444.001.0001"},{"key":"1003_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","volume":"56","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology. 2017;56:95\u2013102.","journal-title":"Rheumatology"},{"key":"1003_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40744-018-0108-4","volume":"5","author":"RH Borse","year":"2018","unstructured":"Borse RH, Kachroo S, Brown C, McCann E, Insinga RP. Cost-effectiveness analysis of golimumab in the treatment of non-radiographic axial spondyloarthritis in Scotland. Rheumatol Ther. 2018;5:57\u201373.","journal-title":"Rheumatol Ther."},{"key":"1003_CR64","doi-asserted-by":"publisher","unstructured":"Sideris E, Soares M, Palmer S. The cost effectiveness of tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Value Health. 2016;A539. Available from: https:\/\/doi.org\/10.1016\/j.jval.2016.09.1116.","DOI":"10.1016\/j.jval.2016.09.1116"},{"key":"1003_CR65","doi-asserted-by":"crossref","unstructured":"Landew\u00e9 RBM. The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology. Lancet Rheumatol. 2021; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2665991321000138.","DOI":"10.1016\/S2665-9913(21)00013-8"},{"key":"1003_CR66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2125.2011.04050.x","volume":"73","author":"D Ternant","year":"2012","unstructured":"Ternant D, Mulleman D, Lauf\u00e9ron F, Vignault C, Ducourau E, Wendling D, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2012;73:55\u201365.","journal-title":"Br J Clin Pharmacol."},{"key":"1003_CR67","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","volume":"7","author":"R Landew\u00e9","year":"2020","unstructured":"Landew\u00e9 R, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch F, Gaffney K, et al. Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE. Rheumatol Ther. 2020;7:581\u201399 This paper demonstrates the value of biologic tapering in the context of a controlled trial.","journal-title":"Rheumatol Ther"},{"key":"1003_CR68","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","volume":"79","author":"RB Landew\u00e9","year":"2020","unstructured":"Landew\u00e9 RB, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020;79:920\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","volume":"21","author":"JW Park","year":"2019","unstructured":"Park JW, Kim H-A, Shin K, Park Y-B, Kim T-H, Song YW, et al. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study. Arthritis Res Ther. 2019;21:163.","journal-title":"Arthritis Res Ther."},{"key":"1003_CR70","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3899\/jrheum.141128","volume":"42","author":"C Plasencia","year":"2015","unstructured":"Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CLM, Turk S, Navarro-Comp\u00e1n V, et al. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J Rheumatol. 2015;42:1638\u201346.","journal-title":"J Rheumatol."},{"key":"1003_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landew\u00e9","year":"2018","unstructured":"Landew\u00e9 R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. Elsevier. 2018;392:134\u201344.","journal-title":"Lancet"},{"key":"1003_CR72","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Comp\u00e1n","year":"2016","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, Balsa A, Mart\u00edn-Mola E, Seoane-Mato D, et al. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology. 2016;55:1188\u201394.","journal-title":"Rheumatology"},{"key":"1003_CR73","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, S\u00f6rensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667\u201375.","journal-title":"Arthritis Rheum."},{"key":"1003_CR74","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439\u201344.","journal-title":"Arthritis Res Ther."},{"key":"1003_CR75","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","volume":"71","author":"I-H Song","year":"2012","unstructured":"Song I-H, Althoff CE, Haibel H, Hermann K-GA, Poddubnyy D, Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71:1212\u20135.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR76","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/art.38014","volume":"65","author":"H Haibel","year":"2013","unstructured":"Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum. 2013;65:2211\u20133.","journal-title":"Arthritis Rheum."},{"key":"1003_CR77","doi-asserted-by":"publisher","first-page":"vi18","DOI":"10.1093\/rheumatology\/key176","volume":"57","author":"H Marzo-Ortega","year":"2018","unstructured":"Marzo-Ortega H, Gaffney KM, Gaffney K. Defining the target: clinical aims in axial spondyloarthritis. Rheumatology. 2018;57:vi18\u201322.","journal-title":"Rheumatology"},{"key":"1003_CR78","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","volume":"74","author":"U Kiltz","year":"2015","unstructured":"Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74:830\u20135.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR79","doi-asserted-by":"crossref","unstructured":"Molt\u00f3 A, L\u00f3pez-Medina C, Van den Bosch F, Boonen A, Webers C, Dernis E, et al. THU0370 cluster-randomized pragmatic clinical trial evaluating the potential benefit of a tight-control and treat-to-target strategy in axial spondyloarthritis: the results of the TICOSPA trial. BMJ Publishing Group Ltd; 2020. Available from: https:\/\/ard.bmj.com\/content\/79\/Suppl_1\/413.1.abstract.","DOI":"10.1136\/annrheumdis-2020-eular.1543"},{"key":"1003_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11926-019-0844-7","volume":"21","author":"D Poddubnyy","year":"2019","unstructured":"Poddubnyy D, Sieper J. Current unmet needs in spondyloarthritis. Curr Rheumatol Rep. 2019;21:43.","journal-title":"Curr Rheumatol Rep."},{"key":"1003_CR81","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/BOR.0b013e328352e0ee","volume":"24","author":"J Sieper","year":"2012","unstructured":"Sieper J. How to screen for axial spondyloarthritis in primary care? Curr Opin Rheumatol. 2012;24:359\u201362.","journal-title":"Curr Opin Rheumatol."},{"key":"1003_CR82","doi-asserted-by":"publisher","first-page":"iv25","DOI":"10.1093\/rheumatology\/keaa472","volume":"59","author":"R Barnett","year":"2020","unstructured":"Barnett R, Ingram T, Sengupta R. Axial spondyloarthritis 10 years on: still looking for the lost tribe. Rheumatology. 2020;59:iv25\u201337.","journal-title":"Rheumatology"},{"key":"1003_CR83","doi-asserted-by":"publisher","first-page":"e000152","DOI":"10.1136\/rmdopen-2015-000152","volume":"1","author":"M van Onna","year":"2015","unstructured":"van Onna M, Gorter S, Maiburg B, Waagenaar G, van Tubergen A. Education improves referral of patients suspected of having spondyloarthritis by general practitioners: a study with unannounced standardised patients in daily practice. RMD Open. 2015;1:e000152.","journal-title":"RMD Open."},{"key":"1003_CR84","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/ken224","volume":"47","author":"RN Jois","year":"2008","unstructured":"Jois RN, Macgregor AJ, Gaffney K. Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatology. 2008;47:1364\u20136.","journal-title":"Rheumatology"},{"key":"1003_CR85","first-page":"2283","volume":"54","author":"MP Sykes","year":"2015","unstructured":"Sykes MP, Doll H, Sengupta R, Gaffney K. Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? Rheumatology. 2015;54:2283\u20134.","journal-title":"Rheumatology"},{"key":"1003_CR86","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrrheum.2012.39","volume":"8","author":"M Rudwaleit","year":"2012","unstructured":"Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol. 2012;8:262\u20138.","journal-title":"Nat Rev Rheumatol."},{"key":"1003_CR87","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/ard.2004.028753","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64:659\u201363.","journal-title":"Ann Rheum Dis."},{"key":"1003_CR88","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1177\/0300060519844871","volume":"47","author":"J Li","year":"2019","unstructured":"Li J, Xu Y, Chen Y, Ye C, Huang J, Qian L, et al. A multidisciplinary clinic approach to improve physician-related diagnostic delay for patients with axial spondyloarthritis: a retrospective study. J Int Med Res. 2019;47:2483\u201391.","journal-title":"J Int Med Res."},{"key":"1003_CR89","doi-asserted-by":"publisher","unstructured":"Steen E, McCrum C, Cairns M. Physiotherapists\u2019 awareness, knowledge and confidence in screening and referral of suspected axial spondyloarthritis: a survey of UK clinical practice. Musculoskeletal Care. 2021; Available from: https:\/\/doi.org\/10.1002\/msc.1537.","DOI":"10.1002\/msc.1537"},{"key":"1003_CR90","doi-asserted-by":"publisher","first-page":"rkz034","DOI":"10.1093\/rap\/rkz034","volume":"3","author":"CY Yong","year":"2019","unstructured":"Yong CY, Hamilton J, Benepal J, Griffiths K, Clark ZE, Rush A, et al. Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK web-based survey. Rheumatol Adv Pract. 2019;3:rkz034.","journal-title":"Rheumatol Adv Pract"},{"key":"1003_CR91","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.physio.2018.11.080","volume":"105","author":"C McCrum","year":"2019","unstructured":"McCrum C, Kenyon K, Cleaton J, Dudley T. An unrecognised masquerader: a retrospective review of people presenting to musculoskeletal physiotherapy with undiagnosed spondyloarthritis. Physiotherapy. Elsevier. 2019;105:e102\u20133.","journal-title":"Physiotherapy. Elsevier"},{"key":"1003_CR92","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/rheumatology\/39.4.369","volume":"39","author":"NP Hurst","year":"2000","unstructured":"Hurst NP, Lambert CM, Forbes J, Lochhead A, Major K, Lock P. Does waiting matter? A randomized controlled trial of new non-urgent rheumatology out-patient referrals. Rheumatology. 2000;39:369\u201376.","journal-title":"Rheumatology"},{"key":"1003_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/bmj.38265.493773.8F","volume":"330","author":"S Hewlett","year":"2005","unstructured":"Hewlett S, Kirwan J, Pollock J, Mitchell K, Hehir M, Blair PS, et al. Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial. BMJ. 2005;330:171.","journal-title":"BMJ."},{"key":"1003_CR94","first-page":"CD011865","volume":"1","author":"L Jia","year":"2021","unstructured":"Jia L, Meng Q, Scott A, Yuan B, Zhang L. Payment methods for healthcare providers working in outpatient healthcare settings. Cochrane Database Syst Rev. 2021;1:CD011865.","journal-title":"Cochrane Database Syst Rev."},{"key":"1003_CR95","doi-asserted-by":"publisher","unstructured":"Scher JU, Schett G. Key opinion leaders \u2014 a critical perspective. Nat Rev Rheumatol. 2021;119\u201324. Available from: https:\/\/doi.org\/10.1038\/s41584-020-00539-1.","DOI":"10.1038\/s41584-020-00539-1"},{"key":"1003_CR96","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305\u201317 This is a seminal paper which describes a personalised approach to biologic selection.","journal-title":"Lancet"},{"key":"1003_CR97","first-page":"90","volume":"1","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med (N Y). 2020;1:90\u2013102.","journal-title":"Med (N Y)."},{"key":"1003_CR98","doi-asserted-by":"publisher","first-page":"106","DOI":"10.18773\/austprescr.2020.037","volume":"43","author":"S Shivakumar","year":"2020","unstructured":"Shivakumar S, Smibert OC, Trubiano JA, Frauman AG, Liew DF. Immunosuppression for COVID-19: repurposing medicines in a pandemic. Aust Prescr. 2020;43:106\u20137.","journal-title":"Aust Prescr."},{"key":"1003_CR99","doi-asserted-by":"crossref","unstructured":"Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. The Lancet Rheumatology. Elsevier; 2020; Available from: https:\/\/www.thelancet.com\/journals\/lanrhe\/article\/PIIS2665-9913(20)30309-X\/fulltext.","DOI":"10.1016\/S2665-9913(20)30309-X"},{"key":"1003_CR100","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3899\/jrheum.170312","volume":"45","author":"LA Bradbury","year":"2018","unstructured":"Bradbury LA, Hollis KA, Gautier B, Shankaranarayana S, Robinson PC, Saad N, et al. Diffusion-weighted imaging is a sensitive and specific magnetic resonance sequence in the diagnosis of ankylosing spondylitis. J Rheumatol. 2018;45:771\u20138.","journal-title":"J Rheumatol."},{"key":"1003_CR101","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nrrheum.2013.83","volume":"9","author":"X Baraliakos","year":"2013","unstructured":"Baraliakos X, Braun J. Opinion: perspectives on imaging in axial spondyloarthritis. Nat Rev Rheumatol. 2013;9:498\u2013502.","journal-title":"Nat Rev Rheumatol."},{"key":"1003_CR102","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41584-019-0309-4","volume":"15","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych WP. The role of imaging in the diagnosis and management of axial spondyloarthritis. Nat Rev Rheumatol. 2019;15:657\u201372 This is an excellent comprehensive review of imaging in axSpA.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01003-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:00:47Z","timestamp":1706180447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01003-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01003-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"PCR reports personal fees from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, and UCB. Research grant funding from UCB, Janssen, and Novartis; non\u00adfinancial support from Pfizer and Bristol\u00adMyers Squibb. DL and JD declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"36"}}